Protara Therapeutics, Inc. Payments to Acquire Available-for-sale Securities
Protara Therapeutics, Inc. (TARA) reported Payments to Acquire Available-for-sale Securities of $15.44 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-20.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2020-03-20
- Protara Therapeutics, Inc. payments to acquire available-for-sale securities for the quarter ending 2018-12-31 was $2.49M, a 66.24% increase year-over-year.
- Protara Therapeutics, Inc. payments to acquire available-for-sale securities for the quarter ending 2018-09-30 was $1.99M, a 88.97% decline year-over-year.
- Protara Therapeutics, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $1.50M.
- Protara Therapeutics, Inc. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $18.08M, a 38.69% increase year-over-year.
- Protara Therapeutics, Inc. payments to acquire available-for-sale securities for fiscal 2018 was $15.44M, a 53.12% decline from fiscal 2017.
- Protara Therapeutics, Inc. payments to acquire available-for-sale securities for fiscal 2017 was $32.94M, a 17.14% decline from fiscal 2016.
- Protara Therapeutics, Inc. payments to acquire available-for-sale securities for fiscal 2016 was $39.76M, a 55.15% decline from fiscal 2015.
- Protara Therapeutics, Inc. payments to acquire available-for-sale securities for fiscal 2015 was $88.64M, a 153.63% increase from fiscal 2014.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2018-12-31 | $2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $4.49M derived: sum of 2 quarters · filed 2020-03-20 | $15.44M 10-K · filed 2020-03-20 | |
| 2018-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $12.95M 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | $10.96M 10-Q · filed 2019-08-07 | |||
| 2017-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $19.58M derived: sum of 2 quarters · filed 2019-03-13 | $32.94M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $18.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $31.44M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $13.36M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $13.04M derived: sum of 2 quarters · filed 2019-03-13 | $16.04M derived: sum of 3 quarters · filed 2019-03-13 | $39.76M 10-K · filed 2019-03-13 |
| 2016-09-30 | $13.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $16.04M derived: sum of 2 quarters · filed 2017-11-07 | $39.76M 10-Q · filed 2017-11-07 | $62.26M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $26.72M 10-Q · filed 2017-08-07 | $49.23M derived: sum of 3 quarters · filed 2018-03-14 | $56.47M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $23.72M 10-Q · filed 2017-05-10 | $46.23M derived: sum of 2 quarters · filed 2018-03-14 | $53.48M derived: sum of 3 quarters · filed 2018-03-14 | $54.23M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $22.51M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $29.75M derived: sum of 2 quarters · filed 2018-03-14 | $30.50M derived: sum of 3 quarters · filed 2018-03-14 | $88.64M 10-K · filed 2018-03-14 |
| 2015-09-30 | $7.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $8.00M derived: sum of 2 quarters · filed 2016-11-07 | $66.14M 10-Q · filed 2016-11-07 | $81.39M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | $751.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $58.89M 10-Q · filed 2016-08-08 | $74.14M derived: sum of 3 quarters · filed 2017-03-16 | $77.05M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $58.14M 10-Q · filed 2016-05-09 | $73.39M derived: sum of 2 quarters · filed 2017-03-16 | $76.29M derived: sum of 3 quarters · filed 2017-03-16 | |
| 2014-12-31 | $15.25M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $18.16M derived: sum of 2 quarters · filed 2017-03-16 | $34.95M 10-K · filed 2017-03-16 | |
| 2014-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $19.70M 10-Q · filed 2015-11-12 | ||
| 2014-06-30 | $16.80M 10-Q · filed 2015-08-13 | |||
| 2013-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $3.88M 10-K · filed 2016-03-14 | ||
| 2013-09-30 | $1.51M 10-Q · filed 2014-11-25 | |||
| 2012-12-31 | $8.66M 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |